**External Validation of A-HIPI in Brazil Registry**

* To discuss: Can we use Brazil + Nordic for validation together or separately? Given authorship, suggest doing these separately.

AMR presented questions from the Brazilian team:

* Some patients with stage IIB disease from the Brazilian Registry were not included in the current analysis because they were not classified as advanced risk groups according to the GHSG risk group. Should these patients be included in the validation study as well?
	+ YES INCLUDE THEM.
* When creating these new variables for hemoglobin, albumin, and lymphocyte count in the format for Holistic validation, those values that did not fulfill the permitted ranges were considered missing values. How should we handle missing data and values out of the permitted ranges?
	+ PRIMARY ANALYSIS EXCLUDED. SENSITIVITY ANALYSIS TO IMPUTE
* We have 19 (2.6%) cases of early death (defined as deaths during ABVD treatment of patients who died of any cause during or up to 30 days after front-line treatment). What do you think about including them in a validation study?
	+ INCLUDE EARLY DEATH.

Notes from Irene (4/7/23 meeting):

* Have done data collection to year 2000
* Have ~1300 patients
* 65% of patients are advanced stage
* Challenge of ongoing engagement